<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30314910</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>46</Issue><PubDate><Year>2018</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6&#xae; cell culture platform is immunogenic and safe in a non-human primate model.</ArticleTitle><Pagination><StartPage>6979</StartPage><EndPage>6987</EndPage><MedlinePgn>6979-6987</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2018.09.068</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(18)31349-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">The World Health Organization recommends the development of affordable next-generation inactivated poliovirus vaccines (IPV) using attenuated poliovirus Sabin strains. Previously, we introduced a novel PER.C6&#xae; cell culture platform, which allows for high yield production of an affordable trivalent Sabin IPV vaccine.</AbstractText><AbstractText Label="METHODS">Immunogenicity and safety of this novel PER.C6&#xae;-based Sabin-IPV (sIPV) was assessed in rats and non-human primates (NHPs). NHPs received one of four different dose dilutions vaccine according to current human schedule (three prime-immunizations and one boost immunization). For comparison, NHPs received commercially available reference Salk IPV or sIPV.</AbstractText><AbstractText Label="RESULTS">Dose-dependent immunogenicity and good tolerability was observed for the PER.C6&#xae;-based sIPV formulations in rats and NHPs. In NHPs, the lowest tested dose that induced anti-Sabin virus-neutralizing antibody titers that were non-inferior to commercial sIPV after three immunizations was 5-7.5-25 D-antigen units for type 1, 2 and 3 respectively.</AbstractText><AbstractText Label="DISCUSSION">PER.C6&#xae;-based sIPV induced comparable immunogenicity to commercial Salk IPV and sIPV vaccines in NHPs. Together with the absence of any preclinical safety signals, these data warrant further testing in clinical trials. sIPV produced on the PER.C6&#xae; cell platform could be one solution to the need for an affordable and immunogenic IPV to achieve and maintain global polio eradication.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bockstal</LastName><ForeName>Viki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Janssen Vaccines and Prevention BV, Archimedesweg 4-6, 2333CN Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiemessen</LastName><ForeName>Machteld M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Janssen Vaccines and Prevention BV, Archimedesweg 4-6, 2333CN Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Achterberg</LastName><ForeName>Rogier</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Janssen Vaccines and Prevention BV, Archimedesweg 4-6, 2333CN Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Wordragen</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Vaccines and Prevention BV, Archimedesweg 4-6, 2333CN Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knaapen</LastName><ForeName>Ad M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Janssen Vaccines and Prevention BV, Archimedesweg 4-6, 2333CN Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serroyen</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Vaccines and Prevention BV, Archimedesweg 4-6, 2333CN Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marissen</LastName><ForeName>Wilfred E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Merus N.V., Yalelaan 62, 3584 CM Utrecht, the Netherlands(2).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuitemaker</LastName><ForeName>Hanneke</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Janssen Vaccines and Prevention BV, Archimedesweg 4-6, 2333CN Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahn</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Janssen Vaccines and Prevention BV, Archimedesweg 4-6, 2333CN Leiden, the Netherlands. Electronic address: rzahn@its.jnj.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016895">Culture Media, Serum-Free</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016895" MajorTopicYN="N">Culture Media, Serum-Free</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IPV</Keyword><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">Inactivated poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">Non-human primates</Keyword><Keyword MajorTopicYN="N">Sabin</Keyword><Keyword MajorTopicYN="N">Salk</Keyword><Keyword MajorTopicYN="N">Toxicity</Keyword><Keyword MajorTopicYN="N">Virus neutralizing assay</Keyword><Keyword MajorTopicYN="N">sIPV</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>11</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30314910</ArticleId><ArticleId IdType="pmc">PMC6219454</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.068</ArticleId><ArticleId IdType="pii">S0264-410X(18)31349-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Polio Eradication and Endgame Strategic Plan 2013&#x2013;2018. Available at: http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf [Accessed 16 February 2018].</Citation></Reference><Reference><Citation>Pliaka V., Kyriakopoulou Z., Markoulatos P. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vacc. 2012;11:609&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">22827246</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor P. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication. Vaccine. 2009;27:2649&#x2013;2652.</Citation><ArticleIdList><ArticleId IdType="pubmed">19428874</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinsbroek E., Ruitenberg E.J. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine. 2010;28:3778&#x2013;3783.</Citation><ArticleIdList><ArticleId IdType="pubmed">20362626</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicking J, Jones R, Nundy N. Improving the affordability of inactivated poliovirus vaccines (IPV) for use in low- and middle-income countries. An economic analysis of strategies to reduce the cost of routine IPV immunization April 20, 2010 PATH Available at http://wwwpathorg/publications/files/TS_IPV_econ_analysispdf [Accessed 29 January 2018].</Citation></Reference><Reference><Citation>Sanders B.P., Oakes Ide L., van Hoek V. Production of high titer attenuated poliovirus strains on the serum-free PER.C6((R)) cell culture platform for the generation of safe and affordable next generation IPV. Vaccine. 2015;33:6611&#x2013;6616.</Citation><ArticleIdList><ArticleId IdType="pubmed">26529068</ArticleId></ArticleIdList></Reference><Reference><Citation>Westdijk J., Brugmans D., Martin J. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines. Vaccine. 2011;29:3390&#x2013;3397.</Citation><ArticleIdList><ArticleId IdType="pubmed">21397718</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato Y., Shiosaki K., Goto Y., Sonoda K., Kino Y. Antibody responses of Macaca fascicularis against a new inactivated polio vaccine derived from Sabin strains (sIPV) in DTaP-sIPV vaccine. Biologicals. 2013;41:184&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">23375165</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceuticals and Medical Devices Agency. Review Report July 12, 2012 for Tetrabik. Available from https://www.pmda.go.jp/files/000153343.pdf [Accessed 09 November 2017].</Citation></Reference><Reference><Citation>Sun M., Ma Y., Xu Y. Dynamic profiles of neutralizing antibody responses elicited in rhesus monkeys immunized with a combined tetravalent DTaP-Sabin IPV candidate vaccine. Vaccine. 2014;32:1100&#x2013;1106.</Citation><ArticleIdList><ArticleId IdType="pubmed">24412578</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao G., Li R., Li C. Phase 3 trial of a Sabin strain-based inactivated poliovirus vaccine. J Infect Dis. 2016;214:1728&#x2013;1734.</Citation><ArticleIdList><ArticleId IdType="pubmed">27658691</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao G., Li R., Li C. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis. 2012;205:237&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">22158682</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada K., Miyazaki C., Kino Y., Ozaki T., Hirose M., Ueda K. Phase II and III clinical studies of diphtheria-tetanus-acellular pertussis vaccine containing inactivated polio vaccine derived from sabin strains (DTaP-sIPV) J Infect Dis. 2013;208:275&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">23568174</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Nonclinical evaluation of vaccines. WHO Technical Report Series, No. 927, 2005. Available at http://www.who.int/biologicals/vaccines/nonclinial_evaluation_of_vaccines/en/ [Accessed 16 February 2018].</Citation></Reference><Reference><Citation>World Health O. Standard procedure for determining immunity to poliovirus using the microneutralization test. WHO/EPI/GEN 93.9, 1993.</Citation></Reference><Reference><Citation>European Pharmacopoeia. In vivo assay of poliomyelitis vaccine (inactivated) monograph 2.7.20. European Pharmacopoeia 8th Edition Volume 1. 8th ed., 2014. p. 255&#x2013;7.</Citation></Reference><Reference><Citation>R Core Team, 2014. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at http://www.R-project.org/ [Accessed 16 February 2018].</Citation></Reference><Reference><Citation>Simizu B., Abe S., Yamamoto H. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals. 2006;34:151&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">16679028</ArticleId></ArticleIdList></Reference><Reference><Citation>Waaijenborg S., Hahne S.J., Mollema L. Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage. J Infect Dis. 2013;208:10&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4043230</ArticleId><ArticleId IdType="pubmed">23661802</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari H., Deshpande J.M., Sutter R.W. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science. 2014;345:922&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10389671</ArticleId><ArticleId IdType="pubmed">25146288</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickley E.B., Strauch C.B., Wieland-Alter W.F. Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent OPV and either high-dose or standard inactivated polio vaccine. J Infect Dis. 2018;217:371&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853416</ArticleId><ArticleId IdType="pubmed">29304199</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker E.P., Molodecky N.A., Pons-Salort M., O'Reilly K.M., Grassly N.C. Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. Expert Rev Vacc. 2015;14:1113&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4673562</ArticleId><ArticleId IdType="pubmed">26159938</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R.W. Unraveling the mucosal immunity of inactivated poliovirus vaccine. J Infect Dis. 2018;217:344&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">29304197</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigdorovich V., Oliver B.G., Carbonetti S. Repertoire comparison of the B-cell receptor-encoding loci in humans and rhesus macaques by next-generation sequencing. Clin Transl Immunol. 2016;5:e93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4973324</ArticleId><ArticleId IdType="pubmed">27525066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kersten G., Hazendonk T., Beuvery C. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine. 1999;17:2059&#x2013;2066.</Citation><ArticleIdList><ArticleId IdType="pubmed">10217607</ArticleId></ArticleIdList></Reference><Reference><Citation>Bockstal V., Sanders B., Achterberg R. A comparative study between outbred and inbred rat strains for the use in in vivo IPV potency testing. Vaccine. 2018;36:2917&#x2013;2920.</Citation><ArticleIdList><ArticleId IdType="pubmed">29685598</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>